Login to Your Account



Not Everyone Impressed

Arena's U.S. Lorcaserin Deal: Eisai Royalties 'Over the Top'

By Randy Osborne


Friday, July 2, 2010
Eisai Inc.'s sales force for the acid reflux therapy Aciphex in the U.S. gives Arena Pharmaceuticals Inc. just the oomph needed to push the obesity drug lorcaserin, due for an FDA panel hearing in September. San Diego-based Arena's stock (NASDAQ:ARNA) closed at $3.56, up 49 cents, or 16 percent, on news of the marketing deal disclosed Thursday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription